Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

INHANCE Stemless omgekeerde schouder IDE

2 november 2026 bijgewerkt door: DePuy Orthopaedics

Gerandomiseerde, prospectieve, multicentrische studie van het INHANCE stemloze totale omgekeerde schoudersysteem

2:1 Randomized, Controlled, Multi-Center, Prospective, Pre-Market Study of the INHANCE Stemless Reverse Cementless Total Shoulder.

Studie Overzicht

Toestand

Actief, niet wervend

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

There is one primary effectiveness endpoint and there are three primary safety endpoints:

  1. Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative

  2. Primary safety endpoint(s):

    1. No revision, removal, reoperation, supplemental fixation, or other intervention for any system component
    2. No humeral or glenoid radiolucent line >2 mm is present in 50% or more zones at 2 years
    3. No conclusive evidence of migration and tilt (>5mm migration and >10° tilt) of the humeral or glenoid component at 2 years

The study will be successful if the primary effectiveness endpoint non-inferiority analysis is successfully demonstrated, and no significant difference is seen on any of the 3 primary safety endpoints.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

168

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Florida
      • Atlantis, Florida, Verenigde Staten, 33462
        • Orthopedic Center of Palm Beach County
    • Massachusetts
      • Waltham, Massachusetts, Verenigde Staten, 02451
        • Boston Bone & Joint Institute BBJI Formerly BSSC
    • Michigan
      • Grand Rapids, Michigan, Verenigde Staten, 49503
        • Trinity Health Grand Rapids
    • Missouri
      • Columbia, Missouri, Verenigde Staten, 65201
        • Missouri Orthopaedic Institute (MOI)
    • North Carolina
      • Charlotte, North Carolina, Verenigde Staten, 28207
        • OrthoCarolina Research Institute Charlotte
      • Raleigh, North Carolina, Verenigde Staten, 27609
        • Duke Orthopaedics of Raleigh
    • Ohio
      • Akron, Ohio, Verenigde Staten, 44333
        • Crystal Clinic Orthopaedic Center
      • Cincinnati, Ohio, Verenigde Staten, 45219
        • Lindner Research Center
      • Cleveland, Ohio, Verenigde Staten, 44195
        • The Cleveland Clinic Foundation
    • Oregon
      • Eugene, Oregon, Verenigde Staten, 97401
        • Slocum Center for Orthopaedics and Sports Medicine
    • Pennsylvania
      • Bethlehem, Pennsylvania, Verenigde Staten, 18015
        • St. Luke's University Health Network
      • Philadelphia, Pennsylvania, Verenigde Staten, 19107
        • Rothman Orthopaedics Institute
    • Tennessee
      • Columbia, Tennessee, Verenigde Staten, 38401
        • MTBJ a division of Tennessee Orthaepedic Alliance
    • Utah
      • Salt Lake City, Utah, Verenigde Staten, 84108
        • University of Utah
    • Virginia
      • Fredericksburg, Virginia, Verenigde Staten, 22408
        • Mary Washington Orthopedics in affiliation with FOA

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

22 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Individuals requiring reverse total shoulder replacement for a severely painful, disabling, arthritic joint (i.e. osteoarthritis, post-traumatic arthritis and rotator cuff arthropathy).
  2. Individuals who are anatomically and structurally suited to receive the implants and have a functional deltoid muscle.
  3. Individuals who are able to read and comprehend the informed patient consent document and are willing and able to provide informed patient consent for participation in the study and have authorized the transfer of their information to DePuy Synthes.
  4. Individuals who are willing and able to return for follow-up as specified by the study protocol.
  5. Individuals who are a minimum age of 22 years at the time of consent.
  6. Individuals who are willing and able to complete the Patient Reported Outcome Measure questionnaires (PROMs) as specified by the study protocol.

Exclusion Criteria:

  1. BMI > 40 kg/m2
  2. Individuals have active, uncontrolled local infection or systemic infection.
  3. Patients who have not reached skeletal maturity, regardless of age.
  4. Either preoperatively or intraoperatively and per standard of care medical assessment, bone stock in the proximal humerus or glenoid fossa is determined to be inadequate for supporting the INHANCE humeral stemless components (NOTE: exclusion applies to both arms of the study, i.e., bone stock to be evaluated independent of randomized treatment assignment).
  5. Intraoperatively and per treating physician's assessment of bone quality, bone is determined to be too soft or porous to support the implant or that is too hard or brittle to allow for proper bone preparation and fixation, i.e. osteoporosis or sclerotic bone, or tumor(s) of the supporting bone structure, where there could be considerable migration of the prosthesis and/or a chance of fracture of the humerus or glenoid.
  6. Fractures of the proximal humerus that could compromise the fixation of the INHANCE reverse humeral stemless components.
  7. Patients who have undergone previous treatment on the study shoulder that may compromise fixation of the INHANCE reverse humeral stemless component.
  8. Revision of a failed hemi, total or reverse shoulder arthroplasty.
  9. Patient is receiving, or is scheduled to receive, treatment that the Investigator considers could affect bone quality, such as chemotherapy or high dose corticosteroids.
  10. Individuals who are bedridden per the Investigator's determination.
  11. Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months.
  12. Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
  13. Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have psychological disorders that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
  14. Patients with a known medical condition that the Investigator believes would impact the study outcomes (including, but not limited to osteomyelitis, Paget's disease, neuropathies such as Charcot's disease, metastatic or neoplastic disorders).
  15. Patient has a medical condition with less than 2 years life expectancy.
  16. Patients who are known to be pregnant or breastfeeding.
  17. Known polyethylene and/or metal sensitivity or allergy.
  18. Contralateral side has been enrolled in the study or has received a total shoulder operation within the last 6 months
  19. Otherwise determined by the investigator to be medically unsuitable for participation in this study
  20. Patient is a member of a vulnerable population (i.e., incarcerated individuals - those incarcerated for at least one month and considered to be an inmate)

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: INHANCE Stemless Reverse

INHANCE(TM) Stemless Reverse Total Shoulder

Uncemented Reverse Total Shoulder

Actieve vergelijker: INHANCE Stemmed Reverse

INHANCE(TM) Stemmed Reverse Total Shoulder

Uncemented Reverse Total Shoulder

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Constant Murley Score (CMS)
Tijdsspanne: Pre-op, 2 years

Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score.

Pre-op, 2 years
Removal of any system component
Tijdsspanne: 2 year

No removal of any system component

2 year
Revision of any system component
Tijdsspanne: 2 year

No revision of any system component

2 year
Reoperation of any system component
Tijdsspanne: 2 year

No reoperation of any system component

2 year
Supplemental Fixation of any system component
Tijdsspanne: 2 year

No supplemental fixation of any system component

2 year
Radiolucent Lines (Humeral & Glenoid)
Tijdsspanne: 2 year

No humeral or glenoid radiolucent line greater than 2mm is present in 50% or more zones

2 year
Migration and Tilt (Humeral & Glenoid)
Tijdsspanne: 2 year

No conclusive evidence of migration and tilt (greater than 5mm migration and greater than 10 degrees tilt) of the humeral or glenoid component

2 year

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Constant Murley Score (CMS)
Tijdsspanne: Pre-op, 3-month, 6-month, 1 year, 2 year

Adjusted Constant-Murley Score at baseline and 3- and 6-months and 1- and 2-years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score.

Pre-op, 3-month, 6-month, 1 year, 2 year
EQ-5D-5L and EQ-VAS
Tijdsspanne: Pre-op, 3-month, 6-month, 1 year, 2 year

EQ-5D-5L Scores by dimension and EQ-VAS, at baseline and 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Simple Shoulder Test
Tijdsspanne: Pre-op, 3-month, 6-month, 1 year, 2 year

Simple Shoulder Test (SST) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Single Assessment Numeric Evaluation (SANE) Score
Tijdsspanne: Pre-op, 3-month, 6-month, 1 year, 2 year

Single Assessment Numeric Evaluation (SANE) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal".

Pre-op, 3-month, 6-month, 1 year, 2 year
Survivorship
Tijdsspanne: 2 year

Overall survivorship of the INHANCE Shoulder System at 2 years post-operative, where the system is deemed to be surviving if no components (humeral stem or stemless component, glenosphere, baseplate, liner, etc.) have been removed for any reason, will be presented using the Kaplan-Meier method.

2 year
Complications
Tijdsspanne: 2 year

The type and frequency of all reportable adverse events (AEs) and device deficiencies in this study will be summarized, with distinction of serious AEs, device and procedure related AEs

2 year

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Constant Murley Score (CMS)
Tijdsspanne: Pre-op, 3-month, 6-month, 1 year

Change from baseline adjusted Constant-Murley Score at 3- and 6-months and 1- year post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score.

Pre-op, 3-month, 6-month, 1 year
EQ-5D-5L and EQ-VAS
Tijdsspanne: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline EQ-5D-5L Value Score and EQ-VAS, at 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Simple Shoulder Test
Tijdsspanne: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline SST Scores at 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Single Assessment Numeric Evaluation (SANE) Score
Tijdsspanne: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline SANE Scores at 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal".

Pre-op, 3-month, 6-month, 1 year, 2 year
Range of Motion
Tijdsspanne: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline range of motion at 3- and 6-months and 1- and 2-years post-operative

Pre-op, 3-month, 6-month, 1 year, 2 year

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

4 maart 2025

Primaire voltooiing (Geschat)

10 november 2027

Studie voltooiing (Geschat)

30 oktober 2028

Studieregistratiedata

Eerst ingediend

27 februari 2024

Eerst ingediend dat voldeed aan de QC-criteria

15 maart 2024

Eerst geplaatst (Werkelijk)

21 maart 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

2 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • DSM202108
  • DSM202108 (Andere identificatie: DePuy Orthopaedics)

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .